For the twelve months ended Jun 30, 2026, Silence Therapeutics Plc reported $615.0K of revenue and -$59.95M of net income.
SLN revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), down 100.0% from a year earlier and down 100.0% from the prior quarter. For the full fiscal 2025 it was $559.0K, down 98.7% from fiscal 2024. It rose in 2 of the last 3 fiscal years.
SLN net income was -$12.27M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$27.35M a year earlier. For the full fiscal 2025 it was -$88.61M, compared with -$45.31M in fiscal 2024.
SLN diluted EPS was -$0.09 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.19 a year earlier. For the full fiscal 2025 it was -$0.63, compared with -$0.33 in fiscal 2024.
SLN free cash flow was $1.52M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$21.83M a year earlier. For the full fiscal 2025 it was -$62.33M, compared with -$67.85M in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $559.0K | $43.26M | $31.64M | $21.66M |
| Cost of revenue | $215.0K | $11.81M | $12.87M | $13.46M |
| Gross profit | $344.0K | $31.45M | $18.78M | $8.19M |
| Research and development | $67.75M | $67.88M | $56.94M | $43.55M |
| Selling, general and admin | $22.34M | $26.88M | $26.22M | $25.68M |
| Operating income | -$91.08M | -$63.32M | -$64.38M | -$61.04M |
| Pre-tax income | -$88.60M | -$44.46M | -$53.27M | -$49.65M |
| Income tax | $11.0K | $845.0K | $956.0K | $688.0K |
| Net income | -$88.61M | -$45.31M | -$54.23M | -$50.33M |
| EPS, basic | -$0.63 | -$0.33 | -$0.49 | -$0.52 |
| EPS, diluted | -$0.63 | -$0.33 | -$0.49 | -$0.52 |
| Diluted shares | 141.7M | 138.8M | 111.3M | 96.6M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $11.28M | $121.33M | $68.79M | - |
| Short-term investments | $73.84M | $26.00M | - | - |
| Receivables | $0 | $972.0K | $290.0K | - |
| Current assets | $118.66M | $187.37M | $103.15M | - |
| Goodwill | $10.62M | $9.39M | $9.98M | $9.68M |
| Total assets | $131.44M | $202.63M | $119.45M | - |
| Current liabilities | $13.61M | $16.82M | $22.34M | - |
| Total liabilities | $69.14M | $68.61M | $97.45M | - |
| Shareholders' equity | $62.30M | $134.02M | $21.99M | $27.22M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$62.27M | -$67.64M | -$49.46M | -$57.04M |
| Capital expenditures | $55.0K | $211.0K | $56.0K | $173.0K |
| Free cash flow | -$62.33M | -$67.85M | -$49.52M | -$57.22M |
| Investing cash flow | -$47.99M | -$21.97M | $19.29M | -$20.50M |
| Financing cash flow | $15.0K | $142.09M | $31.94M | $52.58M |
| Stock-based compensation | $8.07M | $16.31M | $16.27M | $12.69M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue growth, YoY | -98.7% | 36.7% | 46.1% | - |
| Gross margin | 61.5% | 72.7% | 59.3% | 37.8% |
| Operating margin | -16292.8% | -146.4% | -203.5% | -281.9% |
| Net margin | -15851.9% | -104.7% | -171.4% | -232.4% |
| Free cash flow margin | -11149.6% | -156.9% | -156.5% | -264.2% |
| Return on equity | -142.2% | -33.8% | -246.6% | -184.9% |
| Return on assets | -67.4% | -22.4% | -45.4% | - |
| Current ratio | 8.72 | 11.14 | 4.62 | - |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $422.0K | $34.0K | $159.0K | $224.0K | $142.0K | $25.30M | $1.50M | $756.0K | $15.70M |
| Cost of revenue | $0 | $11.0K | $12.0K | $64.0K | $85.0K | $54.0K | $2.04M | $3.64M | $3.33M | $2.80M |
| Gross profit | $0 | $411.0K | $22.0K | $95.0K | $139.0K | $88.0K | $23.27M | -$2.14M | -$2.58M | $12.90M |
| Research and development | $9.15M | $9.12M | $8.75M | $20.54M | $17.65M | $20.81M | $22.08M | $20.16M | $13.80M | $11.85M |
| Selling, general and admin | $4.72M | $7.03M | $3.73M | $5.79M | $5.13M | $7.68M | $5.54M | $7.70M | $7.01M | $6.63M |
| Operating income | -$13.87M | -$15.74M | -$12.46M | -$26.24M | -$23.96M | -$28.41M | -$4.35M | -$30.00M | -$23.39M | -$5.58M |
| Pre-tax income | -$12.27M | -$14.96M | -$11.77M | -$20.96M | -$27.34M | -$28.53M | $12.63M | -$35.49M | -$19.53M | -$2.07M |
| Income tax | $1.0K | $0 | $0 | $1.0K | $10.0K | $0 | $324.0K | $49.0K | $228.0K | $244.0K |
| Net income | -$12.27M | -$14.96M | -$11.77M | -$20.96M | -$27.35M | -$28.53M | $12.30M | -$35.54M | -$19.75M | -$2.31M |
| EPS, basic | -$0.09 | -$0.11 | -$0.09 | -$0.15 | -$0.19 | -$0.20 | $0.08 | -$0.25 | -$0.14 | -$0.02 |
| EPS, diluted | -$0.09 | -$0.11 | -$0.09 | -$0.15 | -$0.19 | -$0.20 | $0.08 | -$0.25 | -$0.14 | -$0.02 |
| Diluted shares | 141.7M | 141.7M | - | 141.7M | 141.7M | 141.7M | - | 141.2M | 140.2M | 131.9M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $72.05M | $5.66M | $11.28M | $82.03M | $41.74M | $64.89M | $121.33M | - | - | - |
| Short-term investments | $0 | $64.42M | $73.84M | $20.16M | $72.42M | $71.65M | $26.00M | - | - | - |
| Receivables | - | $0 | $0 | $28.0K | $85.0K | $41.0K | $972.0K | - | - | - |
| Current assets | $94.28M | $102.85M | $118.66M | $133.63M | $148.55M | $169.79M | $187.37M | - | - | - |
| Goodwill | $10.32M | $10.36M | $10.62M | $10.61M | $10.62M | $10.62M | $9.39M | $9.39M | - | $9.76M |
| Total assets | $106.41M | $115.12M | $131.44M | $146.79M | $165.23M | $185.30M | $202.63M | - | - | - |
| Current liabilities | $12.71M | $10.46M | $13.61M | $17.38M | $14.77M | $19.26M | $16.82M | - | - | - |
| Total liabilities | $67.94M | $65.72M | $69.14M | $72.73M | $71.08M | $72.56M | $68.61M | - | - | - |
| Shareholders' equity | $38.47M | $49.40M | $62.30M | $74.06M | $94.16M | $112.74M | $134.02M | $126.70M | $142.53M | $156.76M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.52M | -$15.60M | -$17.29M | -$10.89M | -$21.78M | -$12.31M | -$27.48M | -$25.61M | -$5.41M | -$9.14M |
| Capital expenditures | $0 | $0 | $0 | $3.0K | $48.0K | $4.0K | $62.0K | $64.0K | $85.0K | $0 |
| Free cash flow | $1.52M | -$15.60M | -$17.29M | -$10.89M | -$21.83M | -$12.31M | -$27.54M | -$25.67M | -$5.49M | -$9.14M |
| Investing cash flow | $64.94M | $10.00M | -$53.34M | $51.29M | -$1.56M | -$44.38M | $66.13M | -$38.14M | -$43.0K | -$49.91M |
| Financing cash flow | $2.0K | $0 | $0 | $0 | $1.0K | $14.0K | -$98.0K | $7.97M | $1.19M | $133.02M |
| Stock-based compensation | $1.31M | $2.45M | -$86.0K | $2.54M | $2.08M | $3.54M | $3.98M | $4.07M | $4.14M | $4.12M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | 197.2% | -99.9% | -89.4% | -70.4% | -99.1% | - | - | - | - |
| Gross margin | - | 97.4% | 64.7% | 59.7% | 62.1% | 62.0% | 91.9% | -142.9% | -340.9% | 82.2% |
| Operating margin | - | -3729.1% | -36650.0% | -16505.7% | -10697.8% | -20006.3% | -17.2% | -2002.5% | -3093.7% | -35.6% |
| Net margin | - | -3544.3% | -34617.6% | -13181.1% | -12211.6% | -20091.5% | 48.6% | -2372.8% | -2613.1% | -14.7% |
| Free cash flow margin | - | -3697.4% | -50844.1% | -6851.6% | -9746.4% | -8671.1% | -108.8% | -1713.7% | -726.7% | -58.2% |
| Current ratio | 7.42 | 9.83 | 8.72 | 7.69 | 10.06 | 8.81 | 11.14 | - | - | - |
Source: XBRL data Silence Therapeutics Plc files with the SEC, latest filing dated Aug 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| SLN | $615.0K | -97.7% | -$59.95M | -9748.5% | $1.23B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |